{"name":"Sunovion Respiratory Development Inc.","slug":"sunovion-respiratory-development-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"SUN-101 via eFlow nebulizer","genericName":"SUN-101 via eFlow nebulizer","slug":"sun-101-via-eflow-nebulizer","indication":"Other","status":"phase_1"},{"name":"Glycopyrrolate Inhalation Solution 200μg","genericName":"Glycopyrrolate Inhalation Solution 200μg","slug":"glycopyrrolate-inhalation-solution-200-g","indication":"Other","status":"phase_2"},{"name":"Seebri® Breezhaler® with activated charcoal","genericName":"Seebri® Breezhaler® with activated charcoal","slug":"seebri-breezhaler-with-activated-charcoal","indication":"Other","status":"phase_1"},{"name":"Placebo eFlow (CS) nebulizer","genericName":"Placebo eFlow (CS) nebulizer","slug":"placebo-eflow-cs-nebulizer","indication":"Placebo control in phase 3 clinical trials for inhaled drug delivery","status":"phase_3"},{"name":"Seebri® Breezhaler®","genericName":"Seebri® Breezhaler®","slug":"seebri-breezhaler","indication":"Other","status":"phase_1"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Placebo administered by Magnair","genericName":"Placebo administered by Magnair","slug":"placebo-administered-by-magnair","indication":"Control comparator in respiratory clinical trials","status":"marketed"}]}],"pipeline":[{"name":"SUN-101 via eFlow nebulizer","genericName":"SUN-101 via eFlow nebulizer","slug":"sun-101-via-eflow-nebulizer","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Glycopyrrolate Inhalation Solution 200μg","genericName":"Glycopyrrolate Inhalation Solution 200μg","slug":"glycopyrrolate-inhalation-solution-200-g","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Seebri® Breezhaler® with activated charcoal","genericName":"Seebri® Breezhaler® with activated charcoal","slug":"seebri-breezhaler-with-activated-charcoal","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo administered by Magnair","genericName":"Placebo administered by Magnair","slug":"placebo-administered-by-magnair","phase":"marketed","mechanism":"Placebo produces no pharmacological effect and serves as a control comparator in clinical trials.","indications":["Control comparator in respiratory clinical trials"],"catalyst":""},{"name":"Placebo eFlow (CS) nebulizer","genericName":"Placebo eFlow (CS) nebulizer","slug":"placebo-eflow-cs-nebulizer","phase":"phase_3","mechanism":"Placebo eFlow (CS) is a vibrating mesh nebulizer device designed to deliver aerosolized medications to the lungs with enhanced efficiency and patient convenience.","indications":["Placebo control in phase 3 clinical trials for inhaled drug delivery"],"catalyst":""},{"name":"Seebri® Breezhaler®","genericName":"Seebri® Breezhaler®","slug":"seebri-breezhaler","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxQTy1XY1p6RVJaTWFJUy03bkhDYnYyUm5HamNFZ1dVQkRiUTNDVmtjRlhvSU9qSi0yX3BkSmo0ZUE4NzUxREZPTm9VSW9NbTZUbHpYVmZMYlc0TVRMZ3NlTlozbWJpci1JY0p0Ykl6aFoySURhUkFzR2VNb3JkdkMzNDd2aXlxNFU5TXFybFBLT21CVTlBU2lCUVczQUphN0c5VjF1UHQ0WDM2c2I1cVRIVk9fNFFMU2xVT2RhamoyanBOaHZxeGs5d3RsaTVpMHFnUVhIVkZ3XzgyYW1VMnc?oc=5","date":"2024-08-22","type":"pipeline","source":"24-7 Press Release Newswire","summary":"Marquis Who's Who Honors Stephen Pham, PhD, for Expertise in Pharmaceuticals and Biotechnology - 24-7 Press Release Newswire","headline":"Marquis Who's Who Honors Stephen Pham, PhD, for Expertise in Pharmaceuticals and Biotechnology - 24-7 Press Release News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQQUV0bGZ3NWtaaF9wU2Jlb1g1TmRVNE5BbF81Ri1oQ2hjczV0VUd4am9lY1hCQjQ2N2h3aENld2NWWVN2QWtaaDM5N2gxcVpHR1Mxa0lxaUNpVG5qUlE1akFtQkNDZ3dBTmdvLUs4XzZhRlVJWkw0Y3UwNEhKb2lwdXZSSE5pamI5WDNQN21NUWRJTHJVMTJQREVmTG0zQVJZTlpPSHliWjE5ZS1Qa2k3eGJfMlBpQ3VnejAtSHgtTnRWZGc?oc=5","date":"2023-12-26","type":"trial","source":"respiratory-therapy.com","summary":"Sunovion Presents Positive Data for its SUN-101 COPD Drug - respiratory-therapy.com","headline":"Sunovion Presents Positive Data for its SUN-101 COPD Drug - respiratory","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOSmp0Q2VOcUh2MmVFa0FEQl85b1RRUDlxUXBkS3hUUHlpYjhKSGRDemN1Y1IxQm04QTQ5aHZfOTlrT0l2OFBKV0R0MUFQWXRwN0xCeEE4OXhaUXVZSUlEbW1SbkZlRjhDbTJDTTBmeTNvUXlPQU9yZE9KMGpYX013TzZINk1UZTVQdEV0WGVuN0E0ZXFMb0F6bVo0RU82NXlmemwwUlR2Y3oyNUtDZVJ1REZGUko4ampkdXVsVTZ3MEI?oc=5","date":"2023-11-09","type":"pipeline","source":"respiratory-therapy.com","summary":"Lonhala Magnair Now Available for COPD - respiratory-therapy.com","headline":"Lonhala Magnair Now Available for COPD - respiratory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxNTGlSOThlVHhmaVk3bDBObmRqYVZYbExjY2pDYkVmWm1nQndXRHVyUEtZVHJtV0VpaWFTR3JDR0ZqamtHSm5WcEV4OEJZVGRrUmZSQm1TUkZQeWNNRlhwVWZWR1IyUHM1cmtRME02RW1wZjJjdmZLQ3RtYzdmUDNMWlg3SWxwbjZpMFBNMmdlbjB3cE9nWjg3VEV5WUFPMlpFWmFZblpseGNBQmZlazEyWm5fMXNVd05zMXFLZUMxMlpqN05JVzFvRndZZEhQZnhwNk9kYk8yeHBCVXc0eHQ3OUQxUU5qd19SOU82alBtdzVDYURVdUUzUjVoYzFRVGFmNWlDeWh6LXY?oc=5","date":"2022-12-01","type":"pipeline","source":"Business Wire","summary":"Otsuka and Sunovion Initiate Clinical Development of Ulotaront for the Adjunctive Treatment of Major Depressive Disorder - Business Wire","headline":"Otsuka and Sunovion Initiate Clinical Development of Ulotaront for the Adjunctive Treatment of Major Depressive Disorder","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNXzdtOGFtckt1eGp3QVo2emVFV2VRQmZaTThjaW9vek1mUFZnUmxyS3psOV9HM1Jod0l3M2VMdWRsVHR4QzdDelRycGFQNE1BQ05Fekl1QTA0X2ZiSXE0R21RR245TldSR0dGcGh3RzdaY290VHlqR2NpX2E3RFNBU0d0bFUwYWQzTmxCd2p5YVhQLUZRNW9QTjRvVDd3SjlRaDRlR2xDS1F6dF9MNFd5Tg?oc=5","date":"2022-10-20","type":"deal","source":"lupin.com","summary":"Lupin Signs Agreement to Acquire Two Inhalation Brands from Sunovion - Lupin | Press Release - lupin.com","headline":"Lupin Signs Agreement to Acquire Two Inhalation Brands from Sunovion - Lupin | Press Release","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxPWEhPR2VFeDRUN0V3TWhBU3dZcmNHa3NIMExSbkdBckhyb0FtcHNRdU9ORy1BblRhd19GOHB5RHZYMUpENk1sdjdSa2txeXdheC1wbkdScll1ZWJtLVZ4dDl5NVY1UXVVUk5CMmc5WkRaaGdLaFQ0M0tBQlRJRzhuX29DajVHVnRWTXJfbE53bk9IOEN1eEEzOE5wekdWbHZPM1Ziem4tVHhvSUM1Mk9ORVBTbkJuUlU2ZE9VbU5feEhuNERwRWFTREFkM1ROdFVQd1BES0t2MTdJcTBQaXlnU2VLYWluQm1wRk9sbTRBYnJ1ZUVNMkhmZDBn?oc=5","date":"2021-09-30","type":"deal","source":"Business Wire","summary":"Sunovion, Sumitomo Dainippon Pharma and Otsuka Enter Worldwide Development and Commercialization Collaboration - Business Wire","headline":"Sunovion, Sumitomo Dainippon Pharma and Otsuka Enter Worldwide Development and Commercialization Collaboration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPbHRRNnpJREVzdHFLaV9ybDB2aWQ2dS13VXZGdXhTY096ZUoxZkE5V3RLOVlxQUpBSTlBUzJHNVh1Y1VmLXUxOVJVMVRCTDd4b0VkRWxqSnNLLUxXM0hYQjVfdHJ2aGxJU2ljSUlUOFdWZ0dFTDF2Q1ZCUm9aaDd4VHlvMU8zRmVyOVYzVnNCYjBmVmxSRV9kdzRNOWROV3RsQVE?oc=5","date":"2017-12-06","type":"regulatory","source":"BioSpace","summary":"Sunovion Snags FDA OK for Lonhala Magnair Inhalation Solution to Treat COPD - BioSpace","headline":"Sunovion Snags FDA OK for Lonhala Magnair Inhalation Solution to Treat COPD","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2017-12-06","type":"regulatory","source":"PR Newswire","summary":"Magnair™ an eFlow® Closed System Nebulizer together with Sunovion's Lonhala™ is the first eFlow technology based product to receive FDA Approval to Treat Chronic Obstructive Pulmonary Disease (COPD) -","headline":"Magnair™ an eFlow® Closed System Nebulizer together with Sunovion's Lonhala™ is the first eFlow technology based product","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPME5iSW5iS201Wm1yTlNSRS11dnJ4bXpPOVJzTkRyRDhHeldvSHpFQzh2OHBUZW1YTEIyTGI1bW5Fcy1VUklQX2FNbjlJN0RMNmJKUW5OS0p4a3JlQWxEcTNQMEZITFh5T3FPQ0FMZXJzWDFOV1dLLVJRcml1RU1TV2ktYXkxeURmRkZHMlIyOHFmZw?oc=5","date":"2016-12-21","type":"deal","source":"drugdiscoverytrends.com","summary":"Novartis Out-Licenses Three COPD Products in the US - drugdiscoverytrends.com","headline":"Novartis Out-Licenses Three COPD Products in the US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNc29lQTE4N1dlLWVuZ2VWU2RUczFRR05FNlRPTmljTS16TGcwUW95Q2VLMk04d3hTVERvTzVraDBNZGdSR2J4SWo3UVZNZ2pULTdhRzdqcXRJRWNndF9QdzVJaVZtbm1oaGFnQkJyUnNMcVRFRElLVnFPV2M2M2puVzBzZ2E5bC1VTHc4QXFPR0hLdzdZRGFxajVqWHdMMUpBUjVVbmdaSVBkWTRiY2hRa3QxVjUxbWVHNU9Z?oc=5","date":"2016-08-18","type":"trial","source":"Clinical Trials Arena","summary":"SUN-101/eFlow for the Treatment of Chronic Obstructive Pulmonary Disease - Clinical Trials Arena","headline":"SUN-101/eFlow for the Treatment of Chronic Obstructive Pulmonary Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxNUl9xNGEtSy1lY05EQ2M2a0ZueEZqOHJrcFFEX0d2a2lFekJVWFpORWZiM1d2YWMtdVdCVnA1b1FJWkdvMGY4WUpUR0N4ZTZtVzVONEdZMHN4OTV1RnkxdHQ5VVZUQUdqT3U2bC1QX0dsR2E0ajRkazhxaG9vWmpvVUo0MjVNeFZFeWxGeG1DX04wczU1WjFyV3RNN05LWmMwTHgwbjVSTXBMc0lrOXQ3MWxkUVRqT1ZDTHVmVThHZEFXRy15YzdMV2s5bw?oc=5","date":"2014-10-01","type":"pipeline","source":"Fierce Pharma","summary":"Sunovion Pharmaceuticals Inc. to Divest Xopenex® (levalbuterol HCI) Inhalation Solution (IS) to Akorn, Inc. - Fierce Pharma","headline":"Sunovion Pharmaceuticals Inc. to Divest Xopenex® (levalbuterol HCI) Inhalation Solution (IS) to Akorn, Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNbnlHMGUzNWxMSVlybUh4QUJjeURUaXhlbGM4UnRFOUh4YTMwanJybzh5ajYwalZfTUpaRVc0VE5ZTHhFdXE4c1Z4aFJDU1YxVU1KeVk1ZXp2RW9uRGFjRlJpZjVjUG9CNjdBX1NRQmtrUXJPSkxieDZQTzdacWNVazNMZmVQTkY5aFhvMUh3TDJETmxZSFUxejhrQ2dSLXFPbHlETkp2ZWJNSTVpNm1xWUpjSjlfRmh1QzhOV2p2SFh2ZkxXdmc?oc=5","date":"2010-10-29","type":"regulatory","source":"Fierce Biotech","summary":"Dainippon Sumitomo Pharma Co., Ltd.'s Sunovion Pharmaceuticals Inc. (SEPR)'s Schizophrenia Pill, Latuda Gets FDA Nod - Fierce Biotech","headline":"Dainippon Sumitomo Pharma Co., Ltd.'s Sunovion Pharmaceuticals Inc. (SEPR)'s Schizophrenia Pill, Latuda Gets FDA Nod","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_1":3,"phase_2":1,"marketed":1,"phase_3":1},"enrichmentLevel":0,"visitCount":7,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}